AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7002430
Drug: Bendroflumethiazide 10
RxNorm normalized name: bendroflumethiazide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 10 mg daily for 10 weeks
Trial: 28060206
Drug: Present Centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present Centered Therapy
Trial: 21353329
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 to 2.5 mg/kg per day, divided in 3 doses)
Trial: 19378635
Drug: Crossing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossing the border to purchase medications (US residents)
Trial: 19378635
Drug: Crossing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossing the border to purchase medications (Ciudad Juarez residents)
Trial: 19378635
Drug: Traveling to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traveling to the United States for medications or health care (Mexican nationals)
Trial: 15163331
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose hydrocortisone (10 mg twice daily)
Trial: 15163331
Drug: Half-dose hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Half-dose hydrocortisone (5 mg twice daily)
Trial: 11798229
Drug: Around-the-clock (ATC)
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Around-the-clock (ATC) opioid therapy, specifically controlled-release oral formulations (e.g. morphine, oxycodone, hydromorphone, hydrocodone)
Trial: 11798229
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of opioids
Trial: 3044723
Drug: Ajmaline (50‐75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline (50‐75 mg i.v.)
Trial: 3044723
Drug: Lidocaine (100‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (100‐200 mg i.v.)
Trial: 25746151
Drug: Standard solutions
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard solutions
Trial: 25746151
Drug: Biocompatible solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible solutions (sensitivity analysis)
Trial: 25746151
Drug: Standard solutions
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard solutions (sensitivity analysis)
Trial: 25746151
Drug: Biocompatible solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible solutions (economic terms)
Trial: 21145052
Drug: Erythromycin 125
RxNorm normalized name: erythromycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 125 mg intravenously 30 minutes before endoscopy
Trial: 21145052
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously 30 minutes before endoscopy
Trial: 17908562
Drug: Active Individual
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Individual Therapy (AIT) for 5 weeks at 3 hours/week
Trial: 17908562
Drug: Active Individual
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Individual Therapy (AIT)
Trial: 11223449
Drug: Micronised fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fenofibrate (267 mg/day) for 12 months
Trial: 11223449
Drug: Micronised fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fenofibrate (267 mg/day) for 3 months
Trial: 11223449
Drug: VLDL-1 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLDL-1 (100 microg apoB/ml)
Trial: 11223449
Drug: VLDL-1 vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLDL-1 vs VLDL-2 at 100 microg apoB/ml
Trial: 11223449
Drug: VLDL-1 vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLDL-1 vs IDL at 100 microg apoB/ml
Trial: 11223449
Drug: Micronised fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fenofibrate (267 mg/day)
Trial: 7955804
Drug: Zolpidem (0.21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (0.21 mg/kg)
Trial: 7955804
Drug: Flumazenil (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.04 mg/kg)
Trial: 3296982
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy withdrawn
Trial: 3296982
Drug: Control (diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (diet and diabetes education without insulin withdrawal)
Trial: 3296982
Drug: Insulin-withdrawal patients
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-withdrawal patients
Trial: 27716696
Drug: Expressed breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressed breast milk (EBM; 0.65 kcal/ml)
Trial: 24897504
Drug: Prophylactic paracetamol
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic paracetamol treatment (24 hours starting at vaccination)
Trial: 24897504
Drug: Therapeutic paracetamol
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic paracetamol treatment (6 hours after vaccination)
Trial: 23415202
Drug: Sequential postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential postoperative antibiotic therapy (i.v. and oral)
Trial: 14974945
Drug: EC‐MPS (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS (720 mg b.i.d.)
Trial: 14974945
Drug: MMF (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF (1000 mg b.i.d.)
Trial: 10443648
Drug: Alprazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.02 mg/kg, administered orally at 0700 h)
Trial: 10443648
Drug: Metyrapone (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (0.04 g/kg, administered orally at 2300 h the night before)
Trial: 373906
Drug: Therapy A
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy A (2 AV followed by 2 CMF)
Trial: 373906
Drug: Therapy B
RxNorm normalized name: Therapy Bayer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy B (2 CMF followed by 2 AV)
Trial: 30772980
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation combined with biofeedback therapy (6 weeks)
Trial: 30772980
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation combined with biofeedback therapy
Trial: 28758341
Drug: Belatacept 4-weekly
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept 4-weekly
Trial: 28758341
Drug: Belatacept 8-weekly
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept 8-weekly
Trial: 23446897
Drug: Choline intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline intake (both 480 mg/d and 930 mg/d)
Trial: 19013258
Drug: Bovine collagen
RxNorm normalized name: Bovine collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine collagen treatment at 15 months
Trial: 16963174
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (ethinyl estradiol 20 microg plus desogestrel 150 microg)
Trial: 15470992
Drug: Experimental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Product E (10% carbamide peroxide gel containing potassium nitrate and sodium fluoride)
Trial: 9428487
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent chemotherapy (platinum analogue or vinorelbine)
Trial: 2721107
Drug: Sublingually administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingually administered buprenorphine (1, 2, and 4 mg)
Trial: 2721107
Drug: Subcutaneously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered buprenorphine (1 and 2 mg)
Trial: 1026545
Drug: Cefadroxil, 0.6-1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil, 0.6-1.8 g per day, given twice or three times daily
Trial: 26294136
Drug: Dextromethorphan (DXM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DXM) 120 mg
Trial: 26294136
Drug: Guaifenesin 400
RxNorm normalized name: guaifenesin 400 MG
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guaifenesin 400 mg
Trial: 22641581
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 in small fractionated doses at each HD session, 3 times per week (group D2S)
Trial: 21448304
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing 13 mg p-synephrine and 176 mg caffeine
Trial: 21448304
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing caffeine and p-synephrine
Trial: 19653920
Drug: Encapsulated FeSO4
RxNorm normalized name: Ferrous Sulfate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Encapsulated FeSO4 (10 mg Fe and 150 microg iodine)
Trial: 19653920
Drug: NutraFine RS
RxNorm normalized name: (RS)-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NutraFine RS (20 mg Fe)
Trial: 17468120
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (100 mg on alternate days)
Trial: 11343977
Drug: Tacrolimus (Tac)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and steroids
Trial: 11343977
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) in combination with mycophenolate mofetil (MMF) and steroids
Trial: 9156357
Drug: Isoprenaline infusion
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline infusion (0.1, 0.2, 0.4, 0.75, and 1.5 micrograms/min for 15 min each)
Trial: 7701049
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) bolus injection of 6 mg benperidol
Trial: 7701049
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration as liquid
Trial: 7701049
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration as tablets
Trial: 3605732
Drug: Diazepam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.15 mg X kg‐1 po
Trial: 25898782
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation (PCS) with propofol (5 mg bolus doses as needed)
Trial: 25898782
Drug: Nurse anesthetist-controlled
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse anesthetist-controlled sedation (ACS) with 2-8 mg/kg/h of propofol
Trial: 25898782
Drug: Midazolam (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (control group) with 2-3 mg for induction and additional 1 mg if required
Trial: 17217818
Drug: 1-day sodium
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-day sodium phosphate bowel preparation
Trial: 17217818
Drug: 3-day magnesium
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day magnesium sulfate bowel preparation
Trial: 12959742
Drug: Altered glycoconjugate
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Altered glycoconjugate metabolism
Trial: 10198901
Drug: 50 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg/day x 5 days (Group I)
Trial: 10198901
Drug: 200 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg/day x 5 days (Group II)
Trial: 10198901
Drug: 400 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/kg/day x 5 days (Group III)
Trial: 10198901
Drug: 200 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg/day x 5 days (second treatment for Group I)
Trial: 10198901
Drug: 400 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/kg/day x 5 days (second treatment for Group II)
Trial: 7774238
Drug: E5 (2
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: E5 (2 mg/kg/day by intravenous infusion 24 hrs apart)
Trial: 2195062
Drug: hGH alone
RxNorm normalized name: hGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH alone (0.1 mg.kg‐1.d‐1)
Trial: 2195062
Drug: Prednisone alone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone alone (0.8 mg.kg‐1.d‐1)
Trial: 27986344
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) to the lung with doses of 50 to 60 Gy in 10-Gy increments.
Trial: 27986344
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) to the left lung.
Trial: 25824533
Drug: Exposure and
RxNorm normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure and response prevention (EX/RP) therapy
Trial: 19847184
Drug: Right-side injection
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right-side injection of 60 mg papaverine
Trial: 19847184
Drug: Left-side injection
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left-side injection of 60 mg papaverine
Trial: 19847184
Drug: Bilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral injection of 30 mg papaverine into each side
Trial: 31378980
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (LNS-LNS)
Trial: 31378980
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (IFA) and children received no supplements (IFA-Control)
Trial: 29973375
Drug: GX-H9 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-H9 (0.1 mg/kg weekly)
Trial: 29973375
Drug: GX-H9 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-H9 (0.3 mg/kg EOW)
Trial: 29973375
Drug: GX-H9 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-H9 (0.2 mg/kg EOW)
Trial: 29973375
Drug: Genotropin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin (6 µg/kg)
Trial: 21038649
Drug: Qishen Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishen Huoxue Granules (QHG) + Continuous Renal Replacement Therapy (CRRT)
Trial: 12857474
Drug: Continuous Renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Renal Replacement Therapy (CRRT)
Trial: 17058826
Drug: Ganneng Dripping
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganneng Dripping Pill (GDP)
Trial: 12837560
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 200 mg administered rectally
Trial: 12837560
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 100 mg administered orally
Trial: 12837560
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 200 mg administered orally
Trial: 8651472
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 1% (Tilarin), QID, 1 spray per nostril
Trial: 6424997
Drug: Bupropion, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion, 100 mg by mouth three times a day for 9 days
Trial: 6424997
Drug: Imipramine, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine, 25 mg by mouth three times a day for 9 days
Trial: 6424997
Drug: Bupropion, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion, 25 mg/kg subcutaneously for 16 days
Trial: 6424997
Drug: Desipramine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine, 5 mg/kg subcutaneously for 16 days
Trial: 26643793
Drug: Supervised training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised training and home‐based rehabilitation program plus educational‐behavioral therapy
Trial: 26643793
Drug: Educational‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational‐behavioral therapy alone
Trial: 25509727
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (oral nimodipine 30 mg three times a day and vinpocetine injection with glucose or saline)
Trial: 23043451
Drug: Arginine L-alpha-ketoglutarate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain (Group I)
Trial: 23043451
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (Group II - no supplement)
Trial: 15650645
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg every 8 hours for 7 days)
Trial: 10613424
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture solution (L‐arginine hydrochloride 100 mg x kg(‐1) + L‐ornithine hydrochloride 80 mg x kg(‐1) + L‐branched chain amino acids 140 mg x kg(‐1))
Trial: 10613424
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture solution (AS)
Trial: 7598296
Drug: Naloxone infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusions
Trial: 30698299
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of amygdalin at 0.6 mg/kg bw
Trial: 30698299
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of amygdalin at 3.0 mg/kg bw
Trial: 30698299
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of crushed bitter apricot seeds at 60 mg/kg bw
Trial: 30698299
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of crushed bitter apricot seeds at 300 mg/kg bw
Trial: 30233114
Drug: Integrated yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated yoga therapy module practices, 1 h/day, 5 days a week for 6 weeks
Trial: 17394891
Drug: Self etching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self etching priming agent (Xeno III)
Trial: 21378375
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated vaccine
Trial: 12868045
Drug: AAS self-administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AAS self-administration for 8 weeks
Trial: 12868045
Drug: AAS self-administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AAS self-administration for 12-16 weeks
Trial: 12868045
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (200 mg/wk i.m.) for 8 weeks
Trial: 12868045
Drug: AAS administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AAS administration regimen and length of abuse
Trial: 1772727
Drug: Subcutaneous suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous suture including a stitch in the fascia
Trial: 1772727
Drug: Subcutaneous suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous suture not including a stitch in the fascia
Trial: 28627976
Drug: Rocuronium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium administered based on fat-free mass
Trial: 28627976
Drug: Rocuronium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium administered based on real body weight